Moderna Stock Review

by admin

Moderna is a biotechnology company that develops vaccines for the treatment of cancer. Its vaccine targets melanoma and helps the body create specialized killer cells that target tumor mutations. Merck recently announced a $250 million deal to exercise an option on the drug, and the two companies plan to test the vaccine in combination with Keytruda.

Moderna has been hurt by concerns about future vaccine revenue. As a result, it wasn’t included in Motley Fool’s list of top 10 stocks. This list was created by a team of financial experts who have successfully beat the market more than three times. The advisor is a long-time investor with a history of beating the market.

Moderna’s pipeline is broad, and it has several vaccines in late-stage trials. The company sees these vaccines as having more than a $1 billion annual sales potential. It also has an expanding pipeline of early-stage vaccines. It also has many opportunities in the cardiovascular and rare diseases sectors.

You may also like

Leave a Comment